Certain head and neck cancer patients benefit from second round of treatment

	Tweet

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings could help guide treatment decisions for head and neck cancer patients.

Radiation is often used to treat patients with head and neck cancer. If their cancer reappears, they have limited treatment choices: chemotherapy is not curative, and surgery can be curative but is often not possible. Chemotherapy and a second course of radiation have previously been shown to be another option. Joseph Salama, MD, formerly of the University of Chicago, and his colleagues conducted an analysis of prior studies to determine how patients tolerate this second round of treatment and which patients benefit the most from it.

The investigators analyzed data from 166 patients with head and neck cancer who received a first round of radiation followed by a second round plus chemotherapy because their cancer recurred or they developed a new tumor. The second course of treatment could cure approximately 25 percent of patients at two years, but it was quite toxic. (Some patients lost the ability to speak or swallow. In addition, approximately 20 percent of patients died from treatment-related complications.)

Certain patients benefited from the treatment over others. Those who were cancer-free for a longer period of time, did not have chemotherapy with their first course of radiation, were treated with a higher dose of radiation in the second round, and had surgery prior to the second course of radiation were more likely to be cured at two years than those who had none or only one of these features. “These can help doctors determine which patients are best suited for a second course of radiation with chemotherapy for head and neck cancer,” said Dr. Salama.

The authors concluded that for patients with recurrent head and neck cancer in a previously irradiated area, concomitant chemotherapy with reirradiation is a treatment option that offers a small but real chance of cure in select patients; however, due to the risk of severe toxicity, the treatment should be limited to investigational studies and experienced medical centers.

###

Contact: Amy Molnar

Wiley-Blackwell

RELATED STORIES:
Some brain tumors mimic the genetic program of germline cells   Target for Therapeutic Drugs to Fight Most Common Adult Brain Cancer   Genetic abnormality offers diagnostic hope for children’s cancer   Acrylamide not tied to thyroid, head-neck cancers   Study finds no brain tumor link with mobile phones   Brain Cancer Experts and Resources at Johns Hopkins   Hyperbaric Oxygen Tested for Aggressive Brain Cancer   Could smoking pot cut risk of head, neck cancer?   Genetic Risk Factor Found for Head and Neck Cancer in Smokers   Gene therapy increases survival for end-stage head and neck cancer   Brain tumors: New therapy surprisingly successful   Dana-Farber Hosting Live Twitter Chat on Head and Neck Cancers   HPV-Positive Tumor Status Indicates Better Survival in Patients with Oropharyngeal Cancer   New technique holds promise for rare eye cancer   Minimizing side effects from chemoradiation could help brain cancer patients live longer   Immune deficiency linked to a type of eye cancer   Radiotherapy Advance Builds Hope for Noninvasive Brain Cancer Treatment   Researchers link dental x-rays to brain tumours   UCSD First to Treat Brain Cancer with Viral Vector   Radiation better than surgery at preserving speech for patients with head and neck cancer   Study Compares Treatment Options for Patients with Brain Metastases   Cotton-Seed Based Drug Shows Promise in Treating Severe Brain Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]